Currently, there are several potential players with promising therapies in the early and mid stages of Pediatric brain tumor clinical trial development. There is an unmet clinical need for a treatment that addresses the root cause of Pediatric brain tumors. Key players, such as Laminar Pharmaceuticals, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech, Candel Therapeutics, Celgene, Kazia Therapeutics, and others, are involved in developing drugs for the Pediatric brain tumors.
DelveInsight’s “Pediatric Brain Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pediatric Brain Tumors market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Pediatric Brain Tumors drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pediatric Brain Tumors treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pediatric Brain Tumors: An Overview
Pediatric central nervous system (CNS) tumors are the second most common childhood malignancy and the most common solid tumor in children Approximately 4,000 children and adolescents in the US are diagnosed with primary brain tumors each year. Primary brain tumors start in the brain and generally do not spread outside the brain tissue. The majority of pediatric tumors are in the posterior fossa (60%). The most common tumors, in decreasing frequency, are Medulloblastoma, juvenile pilocytic astrocytoma (JPA), ependymoma, diffuse intrinsic pontine glioma (DIPG), and atypical teratoid rhabdoid tumor (ATRT).
The other 40% of pediatric brain tumors are in the cerebral hemispheres of the brain. These include astrocytomas, gangliogliomas, craniopharyngiomas, supratentorial primitive neuroectodermal tumors (PNET), germ cell tumors, dysembryoplastic neuroepithelial tumors (DNET), oligodendrogliomas, and meningiomas. Little is known regarding the pathogenesis of most brain tumors in children. There are genetic syndromes that can predispose patients to brain tumors, such as neurofibromatosis type 1 (NF-1), tuberous sclerosis, Li-Fraumeni syndrome, and other less common inherited conditions, such as Gorlin syndrome or Turcot syndrome.
Pediatric Brain Tumors Market Key Facts
Recent data demonstrate that more than 8% of childhood and adolescent cancers arise in the setting of germline predisposition syndromes, and it is likely this number will rise as investigations increase.
According to the study by Johnson et al., there are >100 different histological subtypes of CNS tumors, with the incidence of each varying by age and histologic subtype. Childhood CNS tumor incidence varies by country from 1.12–5.14 cases per 100,000 persons, with the highest incidence in the United States.
According to the American Cancer Society, brain and spinal cord tumors are the second most common cancers in children (after leukemia). They account for about 1 out of 4 childhood cancers. More than 4,000 brain and spinal cord tumors are diagnosed each year in children and teens. The incidence rate (number of tumors per 100,000 children) has not changed much in recent years.
In children, the incidence of brain cancer is approximately 4.84 per 100,000, according to the National Cancer Institute.
Pediatric Brain Tumors Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Pediatric Brain Tumors pipeline therapies. It also thoroughly assesses the Pediatric Brain Tumors market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Pediatric Brain Tumors drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pediatric Brain Tumors Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Pediatric Brain Tumor epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Pediatric Brain tumor epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Pediatric Brain Tumors Epidemiology, Segmented as –
Total Pediatric Brain Tumor Incident Cases
Pediatric Brain Tumors Gender-specific Incident Cases
Pediatric Brain Tumors Diagnosed and Treatable Cases
Pediatric Brain Tumors Type-specific Incident cases
Pediatric Brain Tumors Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pediatric Brain Tumors market or expected to be launched during the study period. The analysis covers the Pediatric Brain Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Pediatric Brain Tumors drugs based on their sale and market share.
The report also covers the Pediatric Brain Tumors pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Pediatric Brain Tumors companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pediatric Brain Tumors Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market
Pediatric Brain Tumors Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Pediatric Brain Tumors. Currently, Midatech Pharma is leading the therapeutics market with its Pediatric Brain Tumors drug candidates in the mid to advanced stage of clinical development.
Pediatric Brain Tumors Companies Actively Working in the Therapeutics Market Include
Midatech Pharma
Y-mAbs Therapeutics
Cellectar Biosciences
ZIOPHARM Oncology
Abbott
Novartis
Laminar Pharmaceuticals
Moleculin Biotech
And Many Others
Emerging and Marketed Pediatric Brain Tumors Therapies Covered in the Report Include:
INXN 2001: ZIOPHARM Oncology
MTX110: Midatech Pharma
AFINITOR (everolimus): Abbott
Everolimus (RAD001): Novartis
LP561A1: Laminar Pharmaceuticals
CLR-131: Cellectar Biosciences
WP1066 (AflacST1901): Moleculin Biotech
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pediatric Brain Tumors Competitive Intelligence Analysis
4. Pediatric Brain Tumors Market Overview at a Glance
5. Pediatric Brain Tumors Disease Background and Overview
6. Pediatric Brain Tumors Patient Journey
7. Pediatric Brain Tumors Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Pediatric Brain Tumors Treatment Algorithm, Current Treatment, and Medical Practices
9. Pediatric Brain Tumors Unmet Needs
10. Key Endpoints of Pediatric Brain Tumors Treatment
11. Pediatric Brain Tumors Marketed Therapies
12. Pediatric Brain Tumors Emerging Drugs and Latest Therapeutic Advances
13. Pediatric Brain Tumors Seven Major Market Analysis
14. Attribute Analysis
15. Pediatric Brain Tumors Market Outlook (In US, EU5, and Japan)
16. Pediatric Brain Tumors Companies Active in the Market
17. Pediatric Brain Tumors Access and Reimbursement Overview
18. KOL Views on the Pediatric Brain Tumors Market
19. Pediatric Brain Tumors Market Drivers
20. Pediatric Brain Tumors Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Nasolabial Fold Market
“Nasolabial Fold Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Nasolabial Fold market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Nasolabial Fold market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/medical-devices
